WO2015049876A1 - 腎機能障害の予防又は改善剤 - Google Patents
腎機能障害の予防又は改善剤 Download PDFInfo
- Publication number
- WO2015049876A1 WO2015049876A1 PCT/JP2014/005049 JP2014005049W WO2015049876A1 WO 2015049876 A1 WO2015049876 A1 WO 2015049876A1 JP 2014005049 W JP2014005049 W JP 2014005049W WO 2015049876 A1 WO2015049876 A1 WO 2015049876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- renal
- nephritis
- renal failure
- rubiprostone
- glomerulonephritis
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Definitions
- the present invention relates to a preventive or ameliorating agent for renal dysfunction, containing lubiprostone or a pharmacologically acceptable salt thereof as an active ingredient.
- the kidney maintains the homeostasis of the body by regulating the concentration of fluid components through excretion and reabsorption, and also functions as an endocrine organ that produces and secretes physiologically active substances such as active vitamin D, erythropoietin, and renin It is an extremely important organ.
- various pathological conditions are caused, resulting in a wide variety of kidney diseases.
- these kidney diseases are nephropathy closely related to diabetes, obesity and lipid metabolism abnormalities, especially diabetic nephropathy whose primary disease is diabetes is strictly controlled after the diagnosis of nephropathy.
- Non-Patent Documents 1 and 2 a urea nitrogen metabolism improving agent containing as an active ingredient at least one selected from the group consisting of flavonoids, saponins or glycosides thereof contained in legumes.
- Patent Document 1 a urea nitrogen metabolism improving agent containing as an active ingredient at least one selected from the group consisting of flavonoids, saponins or glycosides thereof contained in legumes.
- the renal function improving agent which uses the fermentation metabolite of Bifidobacterium as an active ingredient is disclosed (patent document 2). Furthermore, a renal disease ameliorating agent / food “(Nissan Selfie R ” manufactured by Nippon Shokuhin Kako Co., Ltd.) containing dietary fiber obtained from the hulls of food seeds as an active ingredient is disclosed (Patent Document 3).
- Patent Document 3 a renal disease ameliorating agent / food “(Nissan Selfie R ” manufactured by Nippon Shokuhin Kako Co., Ltd.) containing dietary fiber obtained from the hulls of food seeds as an active ingredient is disclosed (Patent Document 3).
- the results show that the survival time of the renal failure rats is simply 2.7 days in the control group and is extended to 3.4 days by administration of the test substance.
- another effect as a renal disease ameliorating agent is not clarified.
- Patent Document 4 a phosphorus adsorbent containing chitosan as an active ingredient is disclosed (Patent Document 4).
- Patent Document 5 low potassium and low phosphorus soy protein for patients with kidney disease
- Patent Document 6 dietary fiber with reduced electrolyte content
- Patent Document 6 dietary fiber composition with reduced phosphorus and potassium content
- Patent Literature 7 Patent Literature 7 and the like are disclosed, however, these methods only improve some of the secondary symptoms (hyperphosphatemia, hyperkalemia, etc.), and clinical effects are recognized. Absent.
- rubiprostone ie, (-)-7-[(2R, 4aR, 5R, 7aR) -2- (1,1-difluoropentyl) -2-hydroxy-6-oxooctahydrocyclopenta [b] pyran- 5-yl] heptanoic acid is a compound of prostaglandins and is generally known to exist in the form of the following tautomers (Patent Document 8).
- Lubiprostone has an effect of improving constipation in which the water content of feces is reduced by activating ClC-2 chloride channel existing in the small intestinal epithelium and promoting water secretion (Patent Document 8, Non-patent Document References 3, 4).
- Sucampo Pharmaceuticals a US subsidiary of Scanpo Pharma, has started clinical research on lubiprostone (trade name: Amitiza [registered trademark]) capsules in the United States, and is currently in the United States and Switzerland, as well as in Japan. Capsules are approved for the treatment of chronic idiopathic constipation.
- rubiprostone has an effect of preventing or improving renal dysfunction is unclear.
- An object of the present invention is to provide a preventive or ameliorating agent for renal dysfunction, which has an excellent inhibitory effect on progression of renal dysfunction, an inhibitory action on renal fibrosis, an inhibitory action on the onset of renal failure, an inhibitory action on nephritis, etc. It is to provide.
- the present inventor has continued eager research to solve the above problems.
- lubiprostone trade name: Amitiza
- rubiprostone has an excellent inhibitory effect on progression of renal dysfunction, It has been found that it has an inhibitory action on renal fibrosis, an onset action on renal failure, and an inhibitory action on nephritis, and has completed the present invention.
- the present invention includes (1) a preventive or ameliorating agent for renal dysfunction characterized by containing lubiprostone or a pharmacologically acceptable salt thereof as an active ingredient, and (2) oral administration.
- the present invention relates to the preventive or ameliorating agent according to (1) or (2) above, wherein the renal dysfunction is renal failure.
- renal dysfunction is prevented by administering the above-mentioned agent for preventing or improving renal dysfunction to a patient in need of prevention or improvement (treatment) of renal dysfunction.
- Method for preventing or improving (treating), rubiprostone or a pharmacologically acceptable salt thereof for use in preventing or improving (treating) renal dysfunction, and the above-mentioned agent for preventing or improving renal dysfunction according to the present invention The use of rubiprostone or a pharmacologically acceptable salt thereof for the preparation of
- Nephritis such as nephritis, tubulointerstitial nephritis, acute pyelonephritis, chronic pyelonephritis, endoproliferative nephritis, lupus nephritis, and other renal failure such as acute renal failure, chronic renal failure, amyloid kidney, membranous nephropathy
- FIG. 3A shows the result of staining the kidney tissue
- FIG. 3B shows the result of staining the whole kidney
- FIG. 3C shows the result of quantifying the staining level of the whole kidney.
- “**” indicates that the rubiprostone 500 administration group has a statistically significant difference (P ⁇ 0.01) in the Dunnett test compared to the corn oil administration group.
- FIG. 5A shows the result of having analyzed the expression of two types of renal failure marker (F4 / 80 and (alpha) SMA) protein in the renal tissue of the chronic renal failure model mouse
- Eight types of renal failure markers (four types of nephritis-related markers [Tnfa, Il6, Pai-1, and Ccl2] [FIG. 5A], and four types of fibrosis-related in renal tissue of chronic renal failure model mice administered with rubiprostone Marker [Col1a1, Col3a1, Tgfb1, and Acta2] [FIG.
- 5B is a diagram showing the results of analyzing the mRNA expression of the gene using a quantitative PCR method.
- “*” indicates that the rubiprostone 50 administration group or the rubiprostone 500 administration group is statistically significant (P ⁇ 0.05) by the Dunnett test compared to the corn oil administration group.
- the preventive or ameliorating agent for renal dysfunction of the present invention contains lubiprostone or a pharmacologically acceptable salt thereof (hereinafter collectively referred to as “rubiprostones”) as an active ingredient, and is necessary.
- lubiprostones a pharmacologically acceptable salt thereof
- binder, stabilizer, excipient, diluent, pH buffer, disintegrant, isotonic agent, additive, coating agent, solubilizer, lubricant Further, a blending component such as a lubricant, a solubilizer, a lubricant, a flavoring agent, a sweetening agent, a solvent, a gelling agent, and a nutrient may be further added.
- ingredients include water, saline, animal fats and oils, vegetable oils, lactose, starch, gelatin, crystalline cellulose, gum, talc, magnesium stearate, hydroxypropyl cellulose, polyalkylene glycol, Polyvinyl alcohol and glycerin can be exemplified.
- Rubiprostone of the present invention is (-)-7-[(2R, 4aR, 5R, 7aR) -2- (1,1-difluoropentyl) -2-hydroxy-6-oxooctahydrocyclopenta [b] pyran- 5-yl] heptanoic acid, usually present in the form of the following tautomers.
- the pharmacologically acceptable salts of lubiprostone of the present invention include metal salts formed from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, N, N′-dibenzylethylenediamine, chloroprocaine, choline , Organic salts generated from diethanolamine, ethylenediamine, N-methylglucamine, lysine, procaine and the like.
- Examples of the administration form of the preventive or ameliorating agent for renal dysfunction of the present invention include oral administration in a dosage form such as powder, granule, tablet, capsule, syrup, suspension, solution, emulsion, suspension. And the like, and parenteral administration in which the dosage form such as injection or spray is administered intranasally, and oral administration is preferred.
- the dosage of the preventive or ameliorating agent for renal dysfunction of the present invention is appropriately determined according to age, weight, sex, symptom, sensitivity to drugs, and the like. Usually, in the dosage range of 1 ⁇ g to 200 mg / day, preferably in the dosage range of 2 ⁇ g to 2000 ⁇ g / day, more preferably in the dosage range of 3 to 200 ⁇ g / day, still more preferably 4 to 20 ⁇ g / day.
- the dose is administered once or multiple times per day (for example, 2 to 4 times) within the day dose range, but the dose may be adjusted according to the state of symptom improvement.
- the rubiprostones which are the active ingredients of the present invention are drugs (trade name: Amitiza) that have already been used for patients with chronic idiopathic constipation, and their usage and side effects are well known.
- Amitiza drugs
- a dose and a dosage form based on those experiences can also be selected.
- the renal dysfunction that is used as a preventive or ameliorating agent for renal dysfunction according to the present invention is not particularly limited as long as it is in a state where some abnormality occurs in the kidney due to disease, trauma, etc., and the renal function is impaired.
- Acute glomerulonephritis minimal change nephritis, chronic glomerulonephritis, nephrosclerosis, membranoproliferative nephritis, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescent nephritis, rapidly progressive Glomerulonephritis, membranous glomerulonephritis, tubulointerstitial nephritis, acute pyelonephritis, chronic pyelonephritis, endoproliferative nephritis, lupus nephritis, and other renal failure such as
- the preventive or ameliorating agent for renal dysfunction according to the present invention containing lubiprostones as an active ingredient can be advantageously applied to a preventive or ameliorating agent for renal fibrosis and an inhibitor (suppressor) for progression of renal dysfunction. it can.
- the preventive or ameliorating agent for renal dysfunction is also useful for preventing or treating inflammatory diseases associated with renal dysfunction. It can be seen that it is. Therefore, the renal dysfunction in the present invention includes inflammatory diseases associated with renal dysfunction for convenience. Such inflammatory diseases include rheumatism, inflammatory bowel disease, hepatitis and the like.
- the above-mentioned rubiprostones can be produced by any known method such as chemical synthesis, production by microorganisms, production by enzymes, etc., but commercially available products can also be used.
- commercially available products such as Amitiza capsule (manufactured by Abbot® Japan) and SPI-0211 (manufactured by Sucampo® Pharmaceuticals) can be mentioned.
- a chronic renal failure model mouse was prepared by feeding adenine and analyzed using the chronic renal failure model mouse. Went.
- Such a chronic renal failure model mouse is a mouse that causes renal damage by crystallization of ingested adenine as insoluble 2,8-dihydroxyadenine in tubules (Cozzolino, M. et al. Kidney Int). 64, 441-450 (2003), Tamagaki, K. et al. Nephrol. Dial. Transplant 21, 651-659 (2006)). All experimental animals were conducted with the consent of the Ethics Committee of Tohoku University School of Medicine.
- Rubiprostone [Amitiza Capsules] [Abbot Japan Co., Ltd.] 50 ⁇ g / kg (mouse body weight) and rubiprostone [Abbot Japan Co., Ltd.] 500 ⁇ g / kg (mouse body weight) dissolved in corn oil once a day for 12 days was administered by oral gavage. [4] After 24 hours, the mouse was removed from the cervical spine.
- FIG. 1 shows the result of measuring the body weight of the mouse at ⁇ 1.86 week).
- the body weight of the chronic renal failure model mice that had decreased from the adenine diet was recovered by returning the diet to the normal diet (see “corn oil administration group” in FIG. 1). It was confirmed that the weight recovery was not affected (see “Lubiprostone 50 administration group” and “Lubiprostone 500 administration group” in FIG. 1).
- Kidney tissue sections were prepared and detailed analysis of kidney tissue was performed.
- the kidney tissue of a chronic renal failure model mouse administered with rubiprostone prepared by the method described in Example 1 was fixed with 10% neutral buffered formalin and embedded in paraffin. Paraffin-embedded kidney tissue was sliced and stained in three different ways (periodate Schiff [PAS] staining, Masson trichrome staining [MTS], and Picrosirius Red staining) (FIG. 3).
- kidney of a chronic renal failure model mouse administered with rubiprostone prepared by the method described in Example 1 was homogenized, and total RNA was extracted and purified with Trizol reagent (manufactured by Invitrogen), and Oligo (dT) primer was used.
- the cDNA was prepared using Transcriptor first strand cDNA cDNA synthesis kit (Roche).
- the mRNA expression levels of the above 8 types of renal failure markers (4 types of nephritis-related markers and 4 types of fibrosis-related markers) were determined by quantitative PCR using Fast start universal probe master (Roche) ) To 2) and detected.
- the GAPDH gene was used as an internal standard.
- TaqMan Gene Expression Assay probe primer set (Applied) as a primer / probe set for amplifying and detecting cDNA of the above 8 types of renal failure markers (4 types of nephritis-related markers and 4 types of fibrosis-related markers) genes Biosystems) was used (see Table 1).
- the relative amount of cDNA of the above 8 types of renal failure markers (4 types of nephritis-related markers and 4 types of fibrosis-related markers), that is, the 8 types of renal failure markers (4 types of nephritis-related markers and 4 types of fibrosis-related markers)
- the relative amount of mRNA of the fibrosis-related marker gene was calculated (see the vertical axis in FIG. 5).
- FIG. 5 shows a comparison between “corn oil administration group” and “normal rearing group” in FIG.
- the present invention it is possible to inhibit the progression of renal dysfunction, suppress renal fibrosis, suppress the onset of renal failure, and suppress nephritis. It contributes to the development of therapeutic agents that prevent the progression of the disease and the therapeutic agents that delay the progression to the introduction of artificial dialysis due to renal dysfunction.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
ルビプロストンを投与した慢性腎不全モデルマウスは、以下の工程〔1〕~〔4〕の方法にしたがって調製した。なお、マウス体重は毎週測定し、血圧はテイルカフ法にて測定した。
〔1〕オスのC57BL/6マウス(日本CLEA株式会社から購入)を、6週齢まで通常飼料(CE-2、日本CLEA社製)にて飼育した。
〔2〕7週齢時に、通常飼料にて飼育した通常飼育群(cont)と、0.2%アデニン(Wako社製)を含む通常飼料(アデニン食[Adenine diet])にて飼育したアデニン食飼育群とに分けた。
〔3〕アデニン食飼育群は、6週間のアデニン食飼育(13週齢)後、飼料を通常飼料に戻し、3種類の投与群(「コーン油投与群」[vehicle]、「ルビプロストン50投与群」[Lubi50]、及び「ルビプロストン500投与群」[Lubi500])に分け、「コーン油投与群」、「ルビプロストン50投与群」、及び「ルビプロストン500投与群」は、それぞれコーン油、コーン油に溶解したルビプロストン[アミティーザカプセル][Abbot Japan社製]50μg/kg(マウス体重)、及びコーン油に溶解したルビプロストン[Abbot Japan社製]500μg/kg(マウス体重)を1日1回、12日間ゾンデにて強制経口投与した。
〔4〕24時間後にマウスを頚椎離脱した。
4種類の群(通常飼育群、コーン油投与群、ルビプロストン50投与群、及びルビプロストン500投与群)について、7週齢(アデニン食飼育直後)、9週齢(アデニン食飼育後2週齢目)、11週齢(アデニン食飼育後4週齢目)、13週齢(ルビプロストン投与直後)、及び、頚椎離脱時(ルビプロストン投与後13/7[≒1.86]週目)のマウス体重を測定した結果を図1に示す。その結果、アデニン食飼育より減少した慢性腎不全モデルマウス体重は、飼料を通常飼料に戻すことで回復したが(図1の「コーン油投与群」参照)、その際、ルビプロストンを投与してもかかる体重回復に影響を及ぼさないことが確認された(図1の「ルビプロストン50投与群」及び「ルビプロストン500投与群」参照)。
実施例1に記載の方法で調製したルビプロストンを投与した慢性腎不全モデルマウスから、定法にしたがって血液を採取し、マウス血中BUN濃度をi-STAT(Fuso社製)を用いて測定した(図2)。その結果、慢性腎不全モデルマウスにおいて、腎機能障害の指標である血中BUN濃度の上昇が認められたのに対して(図2の「コーン油投与群」と「通常飼育群」の比較)、ルビプロストンを投与した慢性腎不全モデルマウスにおいては、ルビプロストンの用量依存的に血中BUN濃度の上昇が抑制された(図2の「ルビプロストン50投与群」及び「ルビプロストン500投与群」と、「コーン油投与群」の比較)。特にルビプロストン500投与群は、コントロールのコーン油投与群に対して有意差が認められた。この結果は、ルビプロストン投与により、腎機能障害を予防又は改善できることを示すとともに、腎機能障害によって引き起こる高血圧も治療・予防できることを示唆している。なお、ルビプロストン投与により血中ヘモグロビン(Hb)濃度は変動しないことが確認されており、この結果から、ルビプロストン投与により血中BUN濃度が抑制されたことは、血液が希釈された結果起こったのではないことが示された。
腎臓の組織切片を作製し、腎臓組織の詳細な解析を行った。実施例1に記載の方法で調製したルビプロストンを投与した慢性腎不全モデルマウスの腎組織を10%中性緩衝ホルマリンで固定し、パラフィン包埋を行った。パラフィン包埋した腎組織をスライスし、3種類の染色法(過ヨウ素酸シッフ[PAS]染色法、マッソン・トリクローム染色[MTS]法、及びピクロシリウスレッド[Picrosirius Red]染色法)組織染色を用いて解析した(図3)。その結果、PAS染色法を用いた解析により、慢性腎不全モデルマウスにおいて、空胞が増加し、尿細管の委縮や消失が認められたのに対して(図3Aの上段[PAS]の「コーン油投与群」と「通常飼育群」の比較)、ルビプロストンを投与した慢性腎不全モデルマウスにおいては、尿細管の回復が認められた(図3Aの上段[PAS]の「ルビプロストン50投与群」及び「ルビプロストン500投与群」と、「コーン油投与群」の比較)。
以上の結果は、上記実施例3の結果を支持するとともに、腎臓の組織レベルの解析から、ルビプロストン投与により、腎繊維化や腎尿細管の減少を抑制できることが確かめられた。
腎不全マーカーとしてF4/80やαSMAが知られている。そこで、これら腎不全マーカータンパク質の発現を指標として、ルビプロストン投与により腎不全の進行が抑制されることを確認した。実施例4で作製した腎臓の組織切片と、抗F4/80抗体(Serotec社製)及び抗αSMA抗体(DAKO社製)を用い、定法にしたがってDAB染色法を行った(図4)。その結果、慢性腎不全モデルマウスにおいて、2種類の腎不全マーカー(F4/80及びαSMA)の発現の増加が認められたのに対して(図4の上段[F4/80]の「コーン油投与群」と「通常飼育群」の比較や、下段[αSMA]の「コーン油投与群」と「通常飼育群」の比較)、ルビプロストンを投与した慢性腎不全モデルマウスにおいては、かかる2種類の腎不全マーカーの発現増加が抑制された(図4の上段[F4/80]の「ルビプロストン50投与群」及び「ルビプロストン500投与群」と、「コーン油投与群」の比較や、下段[αSMA]の「ルビプロストン50投与群」及び「ルビプロストン500投与群」と、「コーン油投与群」の比較)。
2)95℃、15秒と60℃、1分の往復を40サイクル(「Forward Primer」及び「Reverse Primer」によるcDNAの増幅)
以上の結果は、上記実施例3及び4の結果を支持するとともに、腎不全マーカーの発現レベルの解析から、ルビプロストン投与により、腎炎や腎不全発症を予防できることが確かめられた。また、ルビプロストン投与により、各種炎症マーカーの発現量が低下することから、ルビプロストンは、腎機能障害に伴う各種炎症疾患(リウマチ、炎症性腸疾患、肝炎など)の予防又は治療にも有効であることが示唆された。
Claims (4)
- ルビプロストン又はその薬理学的に許容される塩を有効成分として含有することを特徴とする腎機能障害の予防又は改善剤。
- 経口投与することを特徴とする請求項1に記載の予防又は改善剤。
- 腎機能障害が腎炎であることを特徴とする請求項1又は2に記載の予防又は改善剤。
- 腎機能障害が腎不全であることを特徴とする請求項1又は2に記載の予防又は改善剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14851001.9A EP3053575B1 (en) | 2013-10-04 | 2014-10-03 | Agent for preventing or ameliorating renal dysfunction |
JP2015540399A JP6090723B2 (ja) | 2013-10-04 | 2014-10-03 | 腎機能障害の予防又は改善剤 |
US15/026,043 US20160228403A1 (en) | 2013-10-04 | 2014-10-03 | Agent for preventing or ameliorating renal dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-209539 | 2013-10-04 | ||
JP2013209539 | 2013-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015049876A1 true WO2015049876A1 (ja) | 2015-04-09 |
Family
ID=52778479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/005049 WO2015049876A1 (ja) | 2013-10-04 | 2014-10-03 | 腎機能障害の予防又は改善剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160228403A1 (ja) |
EP (1) | EP3053575B1 (ja) |
JP (1) | JP6090723B2 (ja) |
WO (1) | WO2015049876A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01163128A (ja) | 1987-12-18 | 1989-06-27 | Nonogawa Shoji:Kk | 腎機能改善剤 |
JPH0287979A (ja) | 1988-09-26 | 1990-03-28 | Makoto Nagura | 圧電素子による回転アクチュエーター |
JPH02101016A (ja) | 1988-10-05 | 1990-04-12 | Nippon Kayaku Co Ltd | 腎疾患改善剤及び腎疾患改善用食品 |
JPH04210639A (ja) | 1990-11-30 | 1992-07-31 | Dainippon Pharmaceut Co Ltd | 電解質含量を低減化した食物繊維 |
JPH04330015A (ja) * | 1990-04-27 | 1992-11-18 | Ueno Seiyaku Oyo Kenkyusho:Kk | 生化学的拮抗及び疾患処置剤 |
JPH05213762A (ja) | 1992-01-31 | 1993-08-24 | Suzuyo Kk | リン吸着剤 |
JPH0670720A (ja) | 1992-08-26 | 1994-03-15 | Terumo Corp | 食物繊維組成物 |
JPH0770054A (ja) * | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
JPH0832632A (ja) | 1994-07-15 | 1996-02-02 | Toshiba Corp | 伝送方式及びその装置 |
JP2005504836A (ja) * | 2001-08-31 | 2005-02-17 | スキャンポ・アーゲー | クロライドチャンネルオープナーとしてのプロスタグランジンアナログ |
JP2010538016A (ja) * | 2007-08-29 | 2010-12-09 | ソーベント セラピューティクス インコーポレイテッド | 異なる対イオン含有量を有する吸収性ポリマー組成物、ならびにその調製および使用の方法 |
WO2012144649A1 (en) * | 2011-04-19 | 2012-10-26 | Sucampo Ag | Method for modulating cytokine activity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120040025A9 (en) * | 2007-05-04 | 2012-02-16 | Currie Mark G | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention |
-
2014
- 2014-10-03 US US15/026,043 patent/US20160228403A1/en not_active Abandoned
- 2014-10-03 JP JP2015540399A patent/JP6090723B2/ja active Active
- 2014-10-03 WO PCT/JP2014/005049 patent/WO2015049876A1/ja active Application Filing
- 2014-10-03 EP EP14851001.9A patent/EP3053575B1/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01163128A (ja) | 1987-12-18 | 1989-06-27 | Nonogawa Shoji:Kk | 腎機能改善剤 |
JPH0287979A (ja) | 1988-09-26 | 1990-03-28 | Makoto Nagura | 圧電素子による回転アクチュエーター |
JPH02101016A (ja) | 1988-10-05 | 1990-04-12 | Nippon Kayaku Co Ltd | 腎疾患改善剤及び腎疾患改善用食品 |
JPH04330015A (ja) * | 1990-04-27 | 1992-11-18 | Ueno Seiyaku Oyo Kenkyusho:Kk | 生化学的拮抗及び疾患処置剤 |
JPH04210639A (ja) | 1990-11-30 | 1992-07-31 | Dainippon Pharmaceut Co Ltd | 電解質含量を低減化した食物繊維 |
JPH05213762A (ja) | 1992-01-31 | 1993-08-24 | Suzuyo Kk | リン吸着剤 |
JPH0670720A (ja) | 1992-08-26 | 1994-03-15 | Terumo Corp | 食物繊維組成物 |
JPH0770054A (ja) * | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
JPH0832632A (ja) | 1994-07-15 | 1996-02-02 | Toshiba Corp | 伝送方式及びその装置 |
JP2005504836A (ja) * | 2001-08-31 | 2005-02-17 | スキャンポ・アーゲー | クロライドチャンネルオープナーとしてのプロスタグランジンアナログ |
JP4786866B2 (ja) | 2001-08-31 | 2011-10-05 | スキャンポ・アーゲー | クロライドチャンネルオープナーとしてのプロスタグランジンアナログ |
JP2010538016A (ja) * | 2007-08-29 | 2010-12-09 | ソーベント セラピューティクス インコーポレイテッド | 異なる対イオン含有量を有する吸収性ポリマー組成物、ならびにその調製および使用の方法 |
WO2012144649A1 (en) * | 2011-04-19 | 2012-10-26 | Sucampo Ag | Method for modulating cytokine activity |
Non-Patent Citations (7)
Title |
---|
AM. J. PHYSIOL. CELL PHYSIOL., vol. 287, 2004, pages C1173 - 1183 |
AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 292, 2007, pages G647 - 656 |
BRI. J. NUTR., vol. 75, 1996, pages 461 - 469 |
COZZOLINO, M. ET AL., KIDNEY INT, vol. 64, 2003, pages 441 - 450 |
J. NUTR. BIOCHEM., vol. 9, 1998, pages 613 - 620 |
See also references of EP3053575A4 |
TAMAGAKI, K. ET AL., NEPHROL. DIAL. TRANSPLANT, vol. 21, 2006, pages 651 - 659 |
Also Published As
Publication number | Publication date |
---|---|
EP3053575A1 (en) | 2016-08-10 |
EP3053575B1 (en) | 2020-09-02 |
EP3053575A4 (en) | 2017-05-31 |
JP6090723B2 (ja) | 2017-03-08 |
US20160228403A1 (en) | 2016-08-11 |
JPWO2015049876A1 (ja) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6027722B2 (ja) | 脳梗塞の予防及び治療用医薬品の製造におけるl−ブチルフタリドの使用 | |
US20170042924A1 (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
WO2007119837A1 (ja) | リパーゼ阻害剤 | |
JP2007537208A (ja) | 心臓肥大の治療または予防方法 | |
Srimaroeng et al. | Antidiabetic and renoprotective effects of Cladophora glomerata Kützing extract in experimental type 2 diabetic rats: a potential nutraceutical product for diabetic nephropathy | |
KR102271821B1 (ko) | 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물 | |
US20180008665A1 (en) | Methods of treating and preventing gout and lead nephropathy | |
WO2008122190A1 (fr) | Composition comprenant de la l-carnitine ou ses dérivés et son utilisation | |
EP2444078B1 (en) | Use of amides of mono and dicarboxylic acids in the treatment of renal diseases | |
KR102117487B1 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
JP2007126390A (ja) | 血糖値低下剤 | |
JP6090723B2 (ja) | 腎機能障害の予防又は改善剤 | |
WO2022059694A1 (ja) | 腎機能改善用組成物 | |
JP2017052747A (ja) | ウロプラキン発現促進剤 | |
JP2012072136A (ja) | 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び/又は治療用医薬製剤、機能性食品及び健康食品 | |
CA2832059C (en) | Inflammation and immunity treatments | |
KR101706868B1 (ko) | 2-아미노-2-노보네인카복실산을 함유하는 지방간염의 예방 또는 치료용 조성물 | |
JP2008069126A (ja) | 脂肪細胞分化・脂質蓄積調節剤 | |
JP2018177738A (ja) | Trpv4活性抑制剤 | |
KR101706660B1 (ko) | Shp를 유효성분으로 하는 신장질환 예방 및 치료용 조성물 | |
WO2022113693A1 (ja) | 筋ジストロフィー治療剤、中心静脈栄養用組成物、筋組織の炎症抑制剤および筋ジストロフィーの抗炎症用食品組成物 | |
CN116350648B (zh) | 一种用于治疗炎症性肠病的多酚-寡糖复合物及其制备和应用 | |
KR101956528B1 (ko) | 저알부민혈증 개선용 조성물 | |
WO2020130003A1 (ja) | 炎症性疾患およびアレルギー性疾患の治療、予防または改善剤 | |
TWI609689B (zh) | 改善腎臟病患者之腎臟功能和/或心臟功能的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14851001 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2015540399 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014851001 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014851001 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15026043 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |